drugset / Trial / NCT02005211

A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers

NCT02005211

Phase 1 Completed 114 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindBasic science

Summary

This study consists of two parts, ie, single dose part with young healthy subjects (Part 1) and single and multiple dose part with elderly healthy subjects (Part 2), to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD3293 following single and multiple ascending dose administration to healthy subjects.

Timeline

Start
2013-12
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanabecestat Small molecule 15 mg Oral
Subject Lanabecestat Small molecule 50 mg Oral
Subject Lanabecestat Small molecule 150 mg Oral

Indications

No indication recorded.